TerminatedPhase 3

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)

Stopped: Study discontinued as DSMB determined it was futile. No safety concerns were noted.

United States97 participantsStarted 2021-03-18

Plain-language summary

Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC).

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Time to Resolution of Macroscopic Hematuria

Timeframe: Up to 24 weeks

NCT IDNCT04390113

SponsorAlloVir

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-01-30

Results submitted2024-04-18